A phase I study of combination immunotherapy with HSP70 derived peptide, GPC3 derived peptide, IMP321 and Hiltonol for patients with advanced or metastatic solid cancer (A phase I study of combination immunotherapy with HSP70 derived peptide, GPC3 derived peptide, IMP321 and Hiltonol for patients with advanced or metastatic solid cancer)

未提供0 个研究点目标入组 18 人开始时间: 2016年1月12日最近更新: 2020年3月31日

适应症

试验速览

暂无简介。

•1.patients with advanced or metastatic solid cancer (Pancreatic cancer, colon cancer, gastric cancer, esophageal cancer, liver cancer and breast cancer) proven by histology or imaging (CT or MRI)
•Patients with HLA-A*2402 -A*0201 -A*0206
•Standard treatment failure cancer
•Performance Status (PS); 0-1, Eastern Cooperative
•Oncology Group (ECOG)
•Preserved organ functions (number of WBCs more than
•2.0x103/mm3; % of lymphocyte >=15; number of platelets
•>=7.5x103/mm3; hemoglobin >=8.0 g/ dl; creatinine <=2.5
•times of upper normal limit)
•7.Patients provided written, informed consent to participate

•The exclusion criteria were, double cancer, pneumonitis, severe allergy, severe infection, neurological disturbance, uncontrolled general diseases, heart diseases, general steroid treatment, or any prior therapies using same agents of this study.

safety

发起方

未提供